Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionAn old enzyme for current needs: adenosine deaminase and a dendritic cell vaccine for HIV.Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapyIn vivo trafficking and immunostimulatory potential of an intranasally-administered primary dendritic cell-based vaccine.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Developments in clinical cell therapy.Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapiesTherapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.Enhancing immunogenicity and cross-reactivity of HIV-1 antigens by in vivo targeting to dendritic cells.Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation.Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?Improvement of HBsAg gene-modified dendritic cell-based vaccine efficacy by optimizing immunization method or the application of β-glucosylceramide.
P2860
Q26775082-675A9490-B7CB-4DCE-B9F8-316622268797Q30407263-30454C3A-CEC3-4B7E-9B37-498A29726DC3Q33637584-B1E7CBA8-DDE4-4846-95EB-436B543BC67CQ33767127-46A4BC56-7B2A-41C7-A4D4-44DB33CF2313Q33819656-98C835EB-A80D-4299-A6C4-887AAF38AF11Q34157899-BBB38E59-2FC0-4006-BAAA-B751B6D16C59Q34186486-797BE1D8-A312-407C-B4D3-157D45D1DF2BQ36745227-C3FC5E39-3384-4E85-B64D-AEE251CCDD00Q37735515-0CE4EC1C-3345-42DE-A799-B58783D06FBBQ38059499-9A5FBCD4-00DD-4457-AF6C-2B245782FEB8Q38078123-F8419C70-71B5-472A-B356-39A620350023Q41217724-9EC9A3E4-308B-4CF6-9E33-292697E032B7Q42252625-F4640EA9-E414-46C6-9D19-8F4DA398A597Q44408019-670DB30B-D3DA-4E66-A4E0-707A5CF01FCB
P2860
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Production of a dendritic cell ...... ciency virus type 1 infection.
@en
Production of a dendritic cell ...... ciency virus type 1 infection.
@nl
type
label
Production of a dendritic cell ...... ciency virus type 1 infection.
@en
Production of a dendritic cell ...... ciency virus type 1 infection.
@nl
prefLabel
Production of a dendritic cell ...... ciency virus type 1 infection.
@en
Production of a dendritic cell ...... ciency virus type 1 infection.
@nl
P2093
P2860
P356
P1476
Production of a dendritic cell ...... ciency virus type 1 infection.
@en
P2093
Amanda Reiter
Charles R Rinaldo
Joanna Stanson
Nancy C Connolly
Sharon A Riddler
Theresa L Whiteside
P2860
P304
P356
10.1128/CVI.00066-08
P50
P577
2008-11-26T00:00:00Z